Valrubicin
Valrubicin (Valstar) is a chemotherapy washed into the bladder for carcinoma in situ that has not responded to BCG, in patients who cannot yet have their bladder removed.
Overview
Valrubicin was approved in September 1998 for intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would carry unacceptable morbidity or mortality. In the pivotal experience, 230 patients received the drug and about one in five with refractory CIS had a complete response, mostly not durable, so it is a bridge rather than a cure; the label stresses that delaying cystectomy risks progression. Newer options for BCG-unresponsive disease (pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept, TAR-200) have reduced its use. Irritative bladder symptoms and red-tinged urine are expected.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1998 | Intravesical therapy of BCG-refractory carcinoma in situ of the bladder when immediate cystectomy is not acceptable |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Valrubicin" OR ABSTRACT:"Valrubicin" OR TITLE:"Valstar" OR ABSTRACT:"Valstar") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Valrubicin, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductThiotepa
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer and the tag nci-list.
- ProductMitoxantrone
Shares Topoisomerase-I inhibitors (and ADC payloads) and the tag nci-list.
- ProductEpirubicin
Shares Topoisomerase-I inhibitors (and ADC payloads) and the tag nci-list.
- ProductIdarubicin
Shares Topoisomerase-I inhibitors (and ADC payloads) and the tag nci-list.
- ProductDaunorubicin
Shares Topoisomerase-I inhibitors (and ADC payloads) and the tag nci-list.
- CompanyFerring Pharmaceuticals
Shares Nadofaragene firadenovec, Bladder & urothelial cancer.
- CompanyImmunityBio
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
- TermBCG-unresponsive
Shares Nadofaragene firadenovec, Nogapendekin alfa inbakicept, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.